论文部分内容阅读
经卫生部药政局 (96 )ＸＢ 5 0批准文号 ,中国医学科学院肿瘤医院为临床研究负责单位牵头 ,组织 10家医院对临床 4 0 0例消化道肿瘤病人使用阿托氟啶做Ⅱ期临床研究。自 1998年 10月至 2 0 0 1年 1月作者等参加了由山东医科大学和西安制药厂共同开发研制的Ⅰ类抗癌新药阿托氟?
The approval number of the Ministry of Health Pharmaceutical Administration (96) XB50, Cancer Institute of Chinese Academy of Medical Sciences for the lead unit of clinical research, the organization of 10 hospitals on clinical 400 cases of digestive tract cancer patients with atorvastatin do Phase II clinical the study. From October 1998 to January 2001, the author participated in the class I anticancer drug atoFluor developed jointly by Shandong Medical University and Xi’an Pharmaceutical Factory.